Opening Fronts in HIV Vaccine Development: Targeting reservoirs to clear and cure.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.Journal of virology · 2021
   Trial
2. Different Patterns of HIV-1 Replication in MACROPHAGES is Led by Co-Receptor Usage.Medicina (Kaunas, Lithuania) · 2019
   Article
3. Pharmacokinetic stability of macrocyclic peptide triazole HIV-1 inactivators alone and in liposomes.Journal of peptide science : an official publication of the European Peptide Society · 2019
   Article
4. Counteracting Akt Activation by HIV Protease Inhibitors in Monocytes/Macrophages.Viruses · 2018
   Article
5. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.Protein & cell · 2017
   Review
6. Finding a helix in a haystack: nucleic acid cytometry with droplet microfluidics.Lab on a chip · 2017
   Review
7. Profiling the neutralizing antibody response in chronically HIV-1 CRF07_BC-infected intravenous drug users naïve to antiretroviral therapy.Scientific reports · 2017
   Article
8. Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs.The Journal of clinical investigation · 2017
   Article
9. Limited HIV-1 Reactivation in Resting CD4Scientific reports · 2016
   Article
10. An initial examination of the potential role of T-cell immunity in protection against feline immunodeficiency virus (FIV) infection.Vaccine · 2016
    Article
11. Enigma of HIV-1 latent infection in astrocytes: an in-vitro study using protein kinase C agonist as a latency reversing agent.Microbes and infection · 2015
    Article
12. Peptide Triazole Inactivators of HIV-1 Utilize a Conserved Two-Cavity Binding Site at the Junction of the Inner and Outer Domains of Env gp120.Journal of medicinal chemistry · 2015
    Article
13. Eradication of HIV-1 from the macrophage reservoir: an uncertain goal?Viruses · 2015
    Review
14. A new hypothesis on HIV cure.F1000Research · 2015
    Article
15. Immunologic strategies for HIV-1 remission and eradication.Science (New York, N.Y.) · 2014
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as